AEGiS-14IAC: Predicting the HIV set point: comparison of sampling times and methods of set point calculation.

14th International AIDS Conference


Barcelona, Spain - July 7-12, 2002


DonateNow
Print this article

Predicting the HIV set point: comparison of sampling times and methods of set point calculation.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. B10206)

Langan SJ, Sabundayo BP, Bollinger RC, McArthur JH, Quinn TC, Margolick JB
Johns Hopkins University, Baltimore, United States


BACKGROUND: Set point of plasma HIV RNA achieved after primary HIV infection is an important predictor of future disease progression. However, the optimal methods for calculating this set point have not been defined.

METHODS: Participants in the Baltimore site of the Acute HIV Infection and Early Disease Research Program (AIEDRP) who were enrolled within six months of their estimated date of seroconversion (SC), were followed for at least one year with monthly measurements of HIV RNA, and did not receive antiretroviral therapy during this time were studied. Set point was calculated by four

METHODS: 1-3) geometric mean of measurements 100 days to 1 year (100d-1yr), 100 days to 2 years (100d-2yr), and 150 days to 1 year (150d-1yr) after SC, respectively; and 4) the geometric mean of the first two measurements that were within 0.5 log10 units of each other with at least 30 days in between (2 obs 0.5 log10). Correlations between the calculated set points and HIV RNA values at 6, 12, and 18 months after SC were determined.

RESULTS: 34 people contributed data to the analyses. Correlation coefficients were as follows: Time of Plasma HIV Measurements [table: see text]

CONCLUSIONS: A single measurement of plasma HIV RNA in the first year after estimated time of seroconversion generally correlated very strongly with the set point over the first year of infection. Adding a second measurement yielded slightly better correlations.


Keywords: AEGIS, HIV Infections, HIV Seropositivity, Antiretroviral Therapy, Highly Active, Disease Progression, Baltimore, methods, therapy, drug therapyKWDaegis,hivinfections,hivseropositivity,antiretroviraltherapy,highlyactive,diseaseprogression,baltimore,methods,therapy,drugtherapy

020707
B10206

Copyright © 2002 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.